Tech Company Financing Transactions
Noveome Biotherapeutics Funding Round
On 4/10/2019, Noveome Biotherapeutics raised $15 million in Series D funding from private investors.
Transaction Overview
Company Name
Announced On
4/10/2019
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds from the financing will be used to support the advancement of the Company's clinical stage programs investigating its proprietary, cell-free platform biologic, ST266, for the treatment of both ophthalmological and central nervous system (CNS) disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Technology Dr. 200
Pittsburgh, PA 15219
USA
Pittsburgh, PA 15219
USA
Phone
Website
Email Address
Overview
Noveome Biotherapeutics is a clinical applications of a novel secretome -- a rich, complex solution of molecules secreted from proprietary cells. Instead of a single drug and target, our secretome solution contains many biologically active molecules, present in physiological concentrations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Golden
Chief Medical Officer
David Steed
Chief Scientific Officer
Larry Brown
VP - Administration
Maria Weber
VP - Manufacturing
Randall Rupp
VP - Regulatory Affairs
Tammy McCracken
Browse more venture capital transactions:
Prev: 4/10/2019: Avail venture capital transaction
Next: 4/10/2019: Dote venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs